Lumavita tops up its Series A funding with CHF 6 million

Friday 19 June 2009

Location

Switzerland

The Swiss specialty biopharmaceutical company, Lumavita AG, has topped up a recent Series A funding round with CHF 6 million, bringing the total amount raised for commercialising its lead antibiotic product to CHF 24 million.

Full text available to subscribers only. Click here for information on subscribing to MedNous.